Analysis of TPE Treatments With multiFiltratePRO

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorFresenius Medical Care Deutschland GmbH

About this trial

Analysis of therapeutic plasma exchange (TPE) treatments to assess the performance of the TPE mode of multiFiltratePRO based on the successful exchange of plasma from whole blood. The multiFiltratePRO is a device for extracorporeal blood purification treatments.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Body weight ≥40kg irrespective of the age

Patients with indication for TPE treatment according to ASFA guideline

Patients have been treated with TPE between January 2019 and October 2023

Availability of at least 50% of the parameters to be documented for the patient

Disqualifiers

Participation in an interventional clinical study during the retrospectively collected TPE treatment data

Previous documentation within this study

Simultaneous use of another filter for additional therapy form

Trial population

Patients with indication for TPE treatment according to ASFA (American Society for Apheresis) guideline treated with TPE between January 2019 and October 2023.

Trial design

Design model

Other

Time perspective

Retrospective

Treatments tested in this trial

  • Therapeutic Plasma Exchange (TPE) option of multiFiltratePRO

    Device

    Retrospective Data Analysis of TPE treatments with multiFiltratePRO

Treatment groups

60 Participants
are divided into 1 treatment group
Group A: TPE Treatments1 intervention

Trial outcomes

Primary outcomes

1

Total amount of exchange plasma (prescribed vs achieved exchange volume)

Statistical analysis is performed on retrospective data (Treatments between 2019 and October 2023). Primary goal of the study is to prove that the prescribed therapeutic plasma exchange rate during treatment was achieved in \> 70% of treatments and therefore was in alignment with current guidelines.

Time frame
through study completion, an average of 1 year

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Fresenius Medical Care Deutschland GmbH

Lead sponsor

X-act Cologne Clinical Research GmbH

Collaborator